Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
Link externo para Novartis
Novartis compartilhou isso
It was great to talk with Brian Sozzi on Yahoo Finance Opening Bid this week. We talked about Novartis’ successful transition into a fully focused innovative medicines company, creating a culture where everyone feels empowered to pursue new ideas in the face of long odds, and the new technology platforms I believe will define the future of medicine—many of which Novartis is investing in or leading today. I hope you'll check it out. Listen here:
We are happy to partner with the EKHA - European Kidney Health Alliance and RareAware on their campaign driving the awareness of chronic kidney diseases.
The unmet needs are high in rare kidney diseases, which also account for most cases of chronic kidney disease in children. Although there are few therapies approved to treat rare kidney diseases, it is still possible to improve the prognoses through early detection and optimal care. Please join us at the EKHA Kidney Forum on 28 January in the European Parliament to support more focus and better outcomes in common and rare kidney diseases. Register your interest to attend the European Kidney Forum: bit.ly/3Ou3l95 🙏 Franz Schaefer, Professor Dr. Med. Paediatric Nephrology, University Hospital Heidelberg (UKHD), Coordinator of ERKNet, President of IPNA European Renal Association (ERA) EDTNA/ERCA - European Dialysis and Transplant Nurses Association/European Renal Care Association EKPF - European Kidney Patients' Federation Nierstichting International Society of Nephrology ESOT - European Society for Organ Transplantation CompCure
If you lose a child, you lose a generation. No child should die from malaria. But almost 600,000 people died from the disease in 2023, according to the World Health Organization World Malaria Report 2024, which was published today. And most of these deaths were young children in Africa. However, there is hope. Let’s come together to finally defeat malaria. It’s our responsibility. Watch our full film series here: https://lnkd.in/gS9xvAeC Michael Adekunle Charles | Nekoye Otsyula | Abdisalan M. Noor | Bernhards Ogutu
A Multiple Sclerosis (MS) diagnosis can feel difficult to navigate. Five women living with MS tell their story, sharing the importance of understanding their diagnosis and finding their voice in conversations with their care team. Watch Ellen, Trish, Elisabeth, Louisa, and Christina’s stories to learn how they managed their MS journey after their diagnosis. Together, we can advocate for early and accurate diagnosis for everyone living with MS. To learn more about decision making with MS, go to https://lnkd.in/g2RPFMjp
Throughout the year our people give and volunteer to partner organizations across 63 causes and beneficiary areas on company time. To say thanks, Novartis is rewarding generosity with generosity. For the first time, we are matching x5 any donations given by Novartis employees under our Gift of a Gift seasonal employee giving campaign so we can have an even bigger impact on society’s biggest challenges and unmet needs this giving season. #InternationalVolunteerDay https://lnkd.in/gd8SegUu
“Disability and inclusion are important because we know diversity of thought is how we come with innovative ideas, and innovative ideas is how you transform an industry or a sector”. Meet Brian Robbins, our Head Integrated Insights Oncology International. A strong supporter of our Disability-Equity commitments, he is motivated by his personal experiences and hearing loss as a result of a cold, Brian believes inclusion is critical in reaching collective impact, so that we can reimagine medicine, together. Today we’re marking International Day of Persons with Disabilities. Take a few minutes to listen to Brian’s story and reflect on the daily impact that invisible disabilities can have. Learn more about Disability-Equity at Novartis: https://lnkd.in/gwykXNND #PositivelyPurple #ThriveTogether #NovartisTogether
Today, Novartis upgraded our mid-term guidance at our Meet Novartis Management event for investors and analysts in London. As our leadership team outlined, Novartis projects higher sales growth over the next five years. These updated expectations are a result of our robust clinical development program, since transforming into an innovative medicines company. As a result, Novartis now has more than 30 potential high-value medicines in our current pipeline. This revised outlook also builds on the strong momentum outlined in recent quarterly earnings as our current portfolio of breakthrough treatments continues to reach more patients in new markets. We’re excited about the road ahead. And look forward to seeing how these medicines improve and extend patients’ lives in the years to come. You can learn about our updated guidance at https://lnkd.in/eBBf7ZeR #reimaginingmedicine
Innovation only matters when it reaches those who need it. Today, we are honored that Novartis has been ranked first in the 2024 Access to Medicine Index. This recognition reinforces our commitment to improving access to breakthrough medicines for people around the world, regardless of their location or socio-economic status. While we are grateful for this recognition, there is still a large unmet need for medicines —some life-changing, others potentially life-saving— and Novartis is committed to further broaden access to innovation and create sustainable impact. Thank you to our 70,000+ associates and our partners who work tirelessly to make inclusive healthcare a reality. Because every patient matters. Everywhere. #AccessToMedicine #Sustainability #HealthEquity Access to Medicine Foundation
For decades, Novartis has helped lead the fight against chronic myeloid leukemia (CML) through the development of precision breakthrough medicines that improve and extend patients’ lives.
Novartis is on a mission to break down barriers to cardiovascular, renal, and metabolic (CRM) treatments through empathy, access, and innovation. In a recent interview, Dianne Auclair Rocha, SVP and TA Head, Cardiovascular, Renal and Metabolic in the US and Vasilisa Sazonov, Therapy Area Head Cardiovascular, Renal, Metabolic internationally talked about their focus on prevention through education, early screening efforts, and partnerships to reduce access barriers for patients. The leaders emphasized the importance of understanding patient needs and fostering a patient-centered approach, as well as the role of personalized medicine and digital health in the future. Hear more about these leaders' perspectives on the importance of tackling the challenges in the cardiovascular, renal and metabolic space in the article: https://lnkd.in/gTaQHTEJ
NVS
NYSE
20 minutos de atraso
US$ 98,54
Dados de Refinitiv
Ver mais informaçõesÚltima rodada
Dívida pós-IPOUS$ 2.487.694.394,00